Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1883 1
1888 1
1889 1
1890 1
1902 1
1908 1
1912 1
1948 1
1998 1
1999 1
2000 1
2001 6
2002 5
2003 5
2004 9
2005 7
2006 4
2007 4
2008 11
2009 7
2010 11
2011 19
2012 17
2013 13
2014 16
2015 6
2016 14
2017 20
2018 17
2019 30
2020 55
2021 72
2022 41
2023 16
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31559532

355 results

Results by year

Filters applied: . Clear all
Page 1
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators. Arnold DL, et al. Neurology. 2016 Oct 4;87(14):1464-1472. doi: 10.1212/WNL.0000000000003169. Epub 2016 Sep 2. Neurology. 2016. PMID: 27590291 Free PMC article. Clinical Trial.
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.
Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V. Uitdehaag B, et al. Ther Adv Neurol Disord. 2011 Jan;4(1):3-14. doi: 10.1177/1756285610391693. Ther Adv Neurol Disord. 2011. PMID: 21339904 Free PMC article.
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
Kappos L, Kuhle J, Multanen J, Kremenchutzky M, Verdun di Cantogno E, Cornelisse P, Lehr L, Casset-Semanaz F, Issard D, Uitdehaag BM. Kappos L, et al. J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1202-7. doi: 10.1136/jnnp-2014-310024. Epub 2015 Sep 15. J Neurol Neurosurg Psychiatry. 2015. PMID: 26374702 Free PMC article. Clinical Trial.
Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
Traboulsee A, Al-Sabbagh A, Bennett R, Chang P, Li DK; EVIDENCE Study Group; UBC MS/MRI Research Group. Traboulsee A, et al. BMC Neurol. 2008 Apr 21;8:11. doi: 10.1186/1471-2377-8-11. BMC Neurol. 2008. PMID: 18426595 Free PMC article. Clinical Trial.
355 results